netFormulary Dorset NHS
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Updated in accordance with CDF and NICE guidance May 2018. For latest CDF list click here.

Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Cytotoxic Drug Amsacrine
 Track Changes
Formulary
Red
 
   
Cytotoxic Drug Arsenic Trioxide (Trisenox®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line NICE TA526 recommendations.

 
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
   
Cytotoxic Drug Bexarotene (Targretin®)
View adult BNF View SPC online  Track Changes
Formulary
Red
When approved for an individual patient 
   
Cytotoxic Drug Bortezomib (Velcade®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

In accordance with NICE TA (TA129, TA228, TA311) or CDF policy.

 
Link  NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Link  NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
   
Cytotoxic Drug Carfilzomib (Kyprolis®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned in accordance with NICE TA457.

 
Link  NICE TA457: Carfilzomib for previously treated multiple myeloma
   
Cytotoxic Drug Crisantaspase
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned in accordance with NICE TA423 and TA515.

 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (replaces TA250)
Link  NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (not recommended)
   
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online  Track Changes
Formulary
Amber SCG
Hospital initiation. Use in accordance with local shared care guideline. 
Link  Shared care guideline hydroxycarbamide
   
Cytotoxic Drug IxazomibBlack Triangle (Ninlaro®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in accordance with CDF policy and NICE TA505 for use in combination with lenalidomide and dexamethasone if the conditions of the managed access agreement are followed.

 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
   
Cytotoxic Drug Liposomal Cytarabine-Daunorubicin (Vyxeos®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with CDF criteria for untreated, high risk, acute myeloid leukaemia.

 
   
Cytotoxic Drug Lutetium (177Lu) oxodotreotideBlack Triangle (Lutathera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA539.

 
Link  TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
   
Cytotoxic Drug Mitotane (Lysodren®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug NiraparibBlack Triangle (Zejula®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA528.

 
Link  NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
   
Cytotoxic Drug Olaparib (Lynparza®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHSE commissioned for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy in accordance with NICE TA381. 
Link  Class 3 medicines recall: Specific batches of LynparzaTM¥(olaparib) 50mg capsules April 2018
Link  NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
   
Cytotoxic Drug Panobinostat (Farydak®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHSE for treating multiple myeloma after at least 2 previous treatments in accordance with NICE TA380 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Cytotoxic Drug Pegaspargase (Oncaspar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
In accordance with NICE guidance. 
Link  NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
   
Cytotoxic Drug Pentostatin (Nipent® )
View adult BNF View SPC online  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Procarbazine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Talimogene laherparepvec (Imlygic®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

In accordance with NICE guidance.

 
Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
   
Cytotoxic Drug Trabectedin (Yondelis®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England in accordance with NICE guidance.  
Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA185: trabectedin for the treatment of advanced soft tissue sarcoma
   
Cytotoxic Drug Tretinoin
(ATRA, all trans retinoic acid)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Cytotoxic Drug VenetoclaxBlack Triangle (Venclyxto®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned in line with NICE TA487 and CDF recommendations.

 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
   
08.01.05  Expand sub section  Dacarbazine and Temozolomide
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Temozolomide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Commissioned in accordance with NICE TA.

Not routinely commissioned by NHS England for non-malignant endocrinology conditions. As per IFR approval. 
Link  NICE TA121: Carmustin implants and temozolomide for newly diagnosed glioma
Link  NICE TA23: Temozolomide in recurrent malignant glioma (brain cancer)
   
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)
Link  Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
   
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer
   
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online  Track Changes
Formulary
Red
 
Link  Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)
Link  Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
   
08.01.05  Expand sub section  Protein kinase inhibitors
Cytotoxic Drug AfatinibBlack Triangle (Giotrif®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned by NHS England in line with NICE TA310.

 
Link  NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
   
Cytotoxic Drug AlectinibBlack Triangle (Alecensa®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA536 recommendations.

 
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
   
Cytotoxic Drug Axitinib (Inlyta®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned by NHS England in line with NICE TA333.

 
Link  NICE TA 333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Cytotoxic Drug BosutinibBlack Triangle (Bosulif®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA401.

 
Link  NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia
   
Cytotoxic Drug CabozantinibBlack Triangle (Cometriq®, Cabometyx®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Cabometyx®:

  • Commissioned by NHSE in accordance with NICE TA463 for the treatment of previously treated advanced renal cell carcinoma.
  • Commissioned by CDF in line with CDF criteria and NICE TA542 for the treatment of untreated locally advanced or metastatic renal cell carcinoma.
  • Patients initiated on the Named Patient Programme should remain on free of charge stock for the duration of their treatment.

Cometriq®:

  • Commissioned in accordance with NICE TA516 for the first line treatment of medullary thyroid cancer.
 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Cytotoxic Drug CeritinibBlack Triangle (Zykadia®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA395 and TA500.

 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Cytotoxic Drug CrizotinibBlack Triangle (Xalkori®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA529 and NHS England in line with NICE TA406 and TA422.

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
   
Cytotoxic Drug DabrafenibBlack Triangle (Tafinlar®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Commissioned by NHS England in line with NICE TA321 and TA396.

Commissioned by CDF in combination with trametinib for adjuvant treatment of resected BRAF V600 positive malignant melanoma as per CDF criteria and NICE TA544.

 
Link  NICE TA:321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
   
Cytotoxic Drug Dasatinib (Sprycel®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England in line with NICE TA425 and TA426.

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
   
Cytotoxic Drug Erlotinib (Tarceva®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England for cancer, policy in progress. See NICE TA162 and TA374. 
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE374: Erlotinib and Gefitinib for the treatment of non-small-cell lung cancer that has progressed after prior chemotherapy (previously TA162)
Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (not recommended)
   
Cytotoxic Drug Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England in line with NICE TA recommendations.

 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Cytotoxic Drug Gefitinib (Iressa®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England in line with TA192. 
Link  NICE TA192: gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell-lung cancer
Link  NICE TA374: Gefitinib and erlotinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (previously TA175) (not recommended)
   
Cytotoxic Drug Ibrutinib (Imbruvica® )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

In accordance with CDF policy and NICE TA429, TA491 and TA502.

 
Link  NICE TA429:Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Cytotoxic Drug IdelalisibBlack Triangle (Zydelig® )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned in accordance with NICE TA359.

 But NOT in combination with ofatumumab in accordance with as per NICE TA469Black

 
Link  NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia
Link  NICE TA 469: Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)
   
Cytotoxic Drug Imatinib (Generic, Glivec®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

For haematology indications use generic drug, for gastrointestinal stromal tumours use Glivec® brand.

 
Link  NICE TA70: guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (Previously NICETA196)
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
   
Cytotoxic Drug LenvatinibBlack Triangle (Kisplyx®, Lenvima®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Kisplyx®:

  • Commissioned by NHSE in accordance with NICE TA498 for the treatment of previously treated renal cell carcinoma in combination with everolimus.

Lenvima®:

  • Commissioned by NHSE in accordance with NICE TA535 for the treatment of differentiated thyroid cancer after radioactive iodine.
  • Commissioned by CDF in line with CDF criteria for first line treatment of Child Pugh A locally advanced or metastatic hepatocellular carcinoma.
 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
MidostaurinBlack Triangle (Rydapt®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA523 recommendations.

 
Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
   
Cytotoxic Drug Nilotinib (Tasigna®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England in line with NICE TA241 and TA251.

 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Cytotoxic Drug Nintedanib Black Triangle (Vargatef®, Ofev®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Vargatef®:

  • Commissioned by NHS England in line with NICE TA347 for non-small-cell lung cancer.

Restricted Item Ofev®: 

  • Commissioned by NHS England in line with NICE TA379 for idiopathic pulmonary fibrosis via specialist centres only.
 
Link  NICE TA 347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Link  NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
   
Cytotoxic Drug OsimertinibBlack Triangle (Tagrisso®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

In accordance with Cancer Drugs Fund (CDF) and NICE TA recommendations.

 
Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
   
Cytotoxic Drug PalbociclibBlack Triangle (IBRANCE®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned in accordance with NICE TA495 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

Patients inititated on the free of charge patient access programme should continue on free of charge treatment so long as they derive benefit.

 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Cytotoxic Drug Pazopanib (Votrient®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England as per NICE TA215. 
Link  NICE TA215: pazopanib for the first line treatment of advanced renal cell carcinoma
   
Cytotoxic Drug Ponatinib (Iclusig®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned by NHS England in line with NICE TA451.

 
Link  DSU vol 8, iss 4, Nov 2014: S2. Ponatinib (Iclusig): risk of vascular occlusive events
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Cytotoxic Drug RegorafenibBlack Triangle (Stivarga® )
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned in line with NICE TA488.

 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
   
Cytotoxic Drug RibociclibBlack Triangle (Kisqali®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned in accordance with NICE TA496 for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Cytotoxic Drug Ruxolitinib (Jakavi®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England in line with NICE TA386.
 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Cytotoxic Drug Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA474 and by CDF as per NICE TA535 and CDF policy.

 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Cytotoxic Drug Sunitinib (Sutent®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine

For use in line with NICE TA169, TA179 and TA449.

BlueTeq Blueteq prior approval required for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression (TA449).

 
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA178: Renal cell carcinoma (2nd line - not recommended)
   
Cytotoxic Drug TivozanibBlack Triangle (Fotivda®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned in accordance with NICE TA512.

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
Cytotoxic Drug TrametinibBlack Triangle (Mekinist®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA396.

Commissioned by |CDF in line with CDF criteria and NICE TA544.

 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
   
Cytotoxic Drug VandetanibBlack Triangle (Caprelsa®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF (for thyroid cancer) as per CDF policy.

 
   
Cytotoxic Drug Vemurafenib (Zelboraf®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England in line with NICE TA269. 
Link  NICE TA269: vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
   
08.01.05  Expand sub section  Taxanes to top
Cytotoxic Drug Cabazitaxel (Jevtana®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

Commissioned in accordance with NICE guidance.

 
Link  NICE TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Docetaxel
View adult BNF View SPC online  Track Changes
Formulary
Red
 
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
   
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online  Track Changes
Formulary
Red
 
Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Link  NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Cytotoxic Drug Paclitaxel - Albumin Bound Formulation (Nab-paclitaxel) (Abraxane®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA476 in combination with gemcitabine for untreated metastatic pancreatic cancer.

 
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan Hydrochloride
View adult BNF View SPC online  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Topotecan
View adult BNF View SPC online  Track Changes
Formulary
Red

Commissioned by NHS England in line with NICE guidance.

 
Link  NICE TA183: topotecan for the treatment of recurrent and stage IVB cervical cancer
Link  NICE TA184: topotecan for the treatment of relapsed small-cell lung cancer
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Monoclonal antibodies
Cytotoxic Drug AtezolizumabBlack Triangle (Tecentriq®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA492 recommendations.

Commissioned by NHSE in line with NICE TA520 and TA525 recommendations.

Note (July 2018): The European Medicines Agency restricted the use of atezolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. 

 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (only in adults with high levels of PD-L1)
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
   
Cytotoxic Drug AvelumabBlack Triangle (Bavencio®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by NHSE for the treatment of previously treated (with systemic cytotoxic chemotherapy) metastatic Merkel cell carcinoma in line with NICE TA517.

Available via CDF managed access agreement for the treatment of previously untreated (with systemic therapy) metastatic Merkel cell carcinoma - see link below.

 
Link  Managed Access Agreement: Avelumab for treating metastatic Merkel cell carcinoma
Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
   
Cytotoxic Drug Bevacizumab (Avastin®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

For use in line with CDF criteria.

Restricted Item Commissioned by NHS England for neurofibromatosis by NHS England as per national protocol (see NF2 service specification) at specialist centres only.

 
   
Cytotoxic Drug Brentuximab vedotinBlack Triangle (Adcetris®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHSE in line with NICE TA478 and TA524 recommendations.

 
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
   
Cytotoxic Drug Cetuximab (Erbitux®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

For use in line with NICE TA recommendations.

 
Link  NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Link  NICE TA145: Head and neck cancer - cetuximab
Link  NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Link  NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
   
DaratumumabBlack Triangle (DARZALEX® )
View adult BNF View SPC online View SMC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

For use as monotherapy in line with CDF recommendations and NICE TA510 only.

Not recommended for use in combination with lenalidomide and dexamethasone in accordance with NICE TA454.

 
Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA454: Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
   
Durvalumab (Imfinzi®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red

PHT only: Only on direction of Consultant Oncologists, for adult patients with with stage 3 NSCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (cCRT).

This is an unlicensed medicine supplied as part of an 'early access to medicines' (EAMS) scheme until NICE assessment. Prescribers must make patients aware of this & the implications for future funding. 

 
   
Cytotoxic Drug Gemtuzumab ozogamicinBlack Triangle (MYLOTARG®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA545.

 
Link  NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
   
Cytotoxic Drug Inotuzumab ozogamicinBlack Triangle (BESPONSA®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned by CDF in line with CDF criteria and NICE TA541.

 
Link  NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
   
Cytotoxic Drug Ipilimumab (YERVOY ®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

For use in accordance with NICE TA268 and TA319 recommendations.

 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for untreated advanced (unresectable or metastatic) melanoma
   
Cytotoxic Drug NivolumabBlack Triangle (Opdivo®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned in line with CDF criteria and NICE technology appraisal reccomendations.

 
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NIVE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
   
Cytotoxic Drug OlaratumabBlack Triangle (Lartruvo®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
BlueTeq

Commissioned in line with Cancer Drug Fund and NICE TA465 recommendations.

 
Link  NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
   
Cytotoxic Drug Panitumumab (Vectibix®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
BlueTeq

For use in accordance with NICE TA439.

 
Link  NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA240: Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)
Link  NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (not recommended)
   
Cytotoxic Drug PembrolizumabBlack Triangle (Keytruda®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq

Commissioned by the CDF in line with CDF criteria and NICE TA519, TA522 and TA540 recommendations.

Commissioned by NHSE in line with NICE TA357, TA366, TA428 and TA531 recommendations.

 
Link  NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
   
Cytotoxic Drug Pertuzumab (Perjeta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

For use in accordance with NICE TA424 and TA509 recommendations.

 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Trastuzumab (Ontruzant®, Herceptin®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Biosimilar trastuzumab should be used for intravenous treatment where possible.

 
Link  NICE TA107: Breast cancer (early) - trastuzumab
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
   
Cytotoxic Drug Trastuzumab emtansineBlack Triangle (Kadcyla®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned in line with NICE TA458 recommendations.

 
Link  Kadcyla - Prevention of medication errors July 2017
Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
   
 ....
 Non Formulary Items
Cytotoxic Drug  Afatinib  (Giotrif®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
Not recommended by NICE TA 444 for locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy
Link  NICE TA 444 Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
Link  NICE TA 452: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
 
Cytotoxic Drug  Alectinib

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine

Not recommended for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in accordance with NICE TA438

Link  NICE TA438: Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)
 
Cytotoxic Drug  Bortezomib  (Velcade®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black

In accordance with NICE TA 453.

Link  NICE TA Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)
 
Cytotoxic Drug  Cobimetinib hemifumarate  (Cotellic®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine
Not recommended by NICE TA414 for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Link  NICE TA 414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
 
Cytotoxic Drug  Elotuzumab  (Empliciti®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine
In accordance with NICE TA 434
Link  Elotuzumab for previously treated multiple myeloma
 
Cytotoxic Drug  Everolimus  (Votubia®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
High Cost Medicine
Commissioned by NHS England via specialist centres only for:
  • renal angiomyolipoma associated with tubular sclerosis
  • subependymal giantcell astrocytoma (SEGA) associated with tuberous sclerosis complex
  • Link  Clinical Commissioning Policy 16066/P: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
    Link  Clinical Commissioning Policy Statement B14X09: Everolimus for treatment of angiomyolipomas associated with tuberous sclerosis
     
    Cytotoxic Drug  Ibrutinib  (Imbruvica® )

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black

    In accordance with NICE TA 437 and 452

    Link  NICE TA437: Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy
     
    Cytotoxic Drug  Lapatinib  (Tyverb®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine
    Not recommomended by NICE
    Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
     
    Necitumumab  (Portrazza®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine
    Not commissioned because not recommended by NICE.
    Link  NICE TA 411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
     
    Cytotoxic Drug  Nivolumab Black Triangle  (Opdivo®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine

    Nivolumab is not recommended, within its marketing authorisation, for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing therapy as per NICE TA530.

    Link  NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
     
    Cytotoxic Drug  Pegylated Irinotecan Hydrochloride  (Onivyde®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    In accordance with NICE TA 440
    Link  NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
     
    Cytotoxic Drug  Ramucirumab  (Cyramza®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine
    Not recommended by NICE TA 403
    Link  NICE TA 403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
     
    Regorafenib  (Stivarga®)

    Track Changes
    Non Formulary
    Black
    High Cost Medicine

    Not recommended for the treatment of previously treated hepatocellular carcinoma as per NICE TA514.

    Link  NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
     
    Rilonacept

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    High Cost Medicine
    Not routinely commissioned by NHS England (for cryopyrin-associated periodic syndromes). As per IFR approval.
     
    Cytotoxic Drug  Sorafenib

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black

    Not recommended as first or second line for advanced/metastatic renal cell cancer (as in NICE TA178).

    Also not recommended in the treatment of advanced hepatocellular cancer with Child-Pugh gradeB liver impairment (NICE TA474).

     
    Cytotoxic Drug  Temsirolimus  (Torisel®)

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    High Cost Medicine
    NICE do not recommended temsirolimus as a first drug treatments for people with advanced and/or metastatic renal cell carcinoma.
    Link  NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma (not recommended)
    Link  NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
     
    Cytotoxic Drug  Topotecan

    View adult BNF View SPC online View childrens BNF Track Changes
    Non Formulary
    Black
    Not recommended within its marketing authorisation for treating:
    - first recurrence of platinum‑sensitive ovarian cancer
    - recurrent platinum‑resistant or platinum‑refractory ovarian cancer -NICE TA 389


    Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
     
    Cytotoxic Drug  Vismodegib Black Triangle  (Erivedge®)

    View adult BNF View SPC online Track Changes
    Non Formulary
    Black
    High Cost Medicine

    Following the publication of the negative NICE TA489 on 22/11/2017 vismodegib was de-listed from the CDF on 22/01/2018. No longer routinely commissioned.

    Link  NICE TA489: Vismodegib for treating basal cell carcinoma (not recommended)
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Green

    May be initiated, stabilised and maintained in primary, secondary or tertiary care  

    Amber

    Amber drug - without shared care  

    Amber SCG

    Amber drug - with shared care guideline  

    Red

    For secondary or tertiary care initiation and long-term maintenance of prescribing  

    Black

    Not recommended  

    netFormulary